AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist, extracted from patent WO2020168017 A1. AXC-715 trihydrochloride, compound D from WO2020190734A1, can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants.
性状
Solid
IC50 & Target[1][2]
TLR7/TLR8
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
参考文献
[1]. Sung-Ju Moon, et al. Compositions containing, methods and uses of antibody-tlr agonist conjugates. Patent WO2020168017A1.[2]. Shelley Erin ACKERMAN, et al. Immunoconjugates targeting pd-l1. Patent WO2020190734A1.
溶解度数据
In Vitro: DMSO : 125 mg/mL (297.05 mM; Need ultrasonic)配制储备液